Francesco Maura, MD discusses a study presented that uses whole genome sequencing to predict patient outcomes after anti-BCMA CAR-T therapy for multiple myeloma. The research highlights how specific genomic alterations can influence therapy response, suggesting a more personalized approach to treatment and the potential for targeting other therapies for patients with genomic instability.

Link to ASH playlist: [ Ссылка ]

ASH Abstract: Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
#ASH24 #Myeloma #mmsm

Follow HealthTree:
[ Ссылка ]
twitter.com/healthtreeformm
facebook.com/healthtreeformultiplemyeloma
instragram.com/healthtreeformultiplemyeloma

свернуть